Boston-based Elicio Therapeutics (Nasdaq: ELTX) reported that its AMPLIFY-7P trial of ELI-002 7P, a lymph node-targeted mutant KRAS peptide immunotherapy, did not meet its pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat population of patients with resected, stage I–III mKRAS-driven pancreatic ductal adenocarcinoma (PDAC). The miss matters because it keeps ELI-002 7P from a straightforward path to Phase III and leaves the adjuvant PDAC setting — where no approved therapies exist — still without a validated treatment candidate.
The story, however, is more complicated than a clean failure. A post-hoc analysis in the R0 completely resected subgroup (n=121, approximately 84% of enrolled patients) showed a statistically significant DFS improvement: HR 0.65, p=0.048, with a median DFS of 23.8 months versus 12.8 months for observation. An imbalance in baseline R1 resection status — a known adverse prognostic factor — disproportionately burdened the ELI-002 7P arm (19% vs. 10% in the observation arm), which Elicio argues meaningfully confounded the ITT result. Multivariable analysis confirmed R1 resection as an adverse prognostic factor for recurrence (HR 1.56), lending some biological plausibility to the company's interpretation. Landmark analyses during active treatment at three months (90.3% vs. 76.6%, p=0.022) and six months (75.7% vs. 61.7%, p=0.056) also suggested early clinical activity, with arm separation persisting through nine months.
The most striking data point is the correlation between mKRAS-specific T cell responses and DFS outcomes. In 90 evaluable patients, those with the strongest immune responses (T cell fold-change >9.17x from baseline) demonstrated an HR of 0.22 versus lower responders (p<0.0001) — a relationship that supports genuine biological activity of the lymph node-targeted AMP platform. ELI-002 7P delivers AMP-modified KRAS peptide antigens alongside an AMP-modified CpG adjuvant (ELI-004), exploiting albumin trafficking to concentrate immune activation in lymph nodes. Safety was clean: no treatment-related discontinuations, no treatment-related deaths, and proportionally fewer adverse events in the ELI-002 7P arm than in the observation arm.
The biological signal is notable, but all subgroup and landmark analyses are post-hoc, and cross-trial comparisons are limited. The R0 DFS benefit, while statistically significant, derives from a subset of a relatively small trial and requires prospective confirmation before it can support regulatory claims.
Competitive context and strategic pressure
The adjuvant PDAC immunotherapy space is active. BioNTech's autogene cevumeran, a personalized mRNA neoantigen vaccine, has shown persistent T cell responses and longer recurrence-free survival in responders in Phase I data. Elicio's ELI-002 7P is an off-the-shelf approach targeting seven common KRAS mutations, which it argues offers manufacturing and access advantages over personalized approaches. The two programs are not directly comparable — different mechanisms, patient selection, and trial designs — but they compete for the same clinical hypothesis: that immune priming after surgery can delay or prevent PDAC recurrence.